Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine 22 October 2021
Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss 24 September 2021
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts 24 June 2021
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 31 May 2021
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment 20 May 2021
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra® 29 April 2021
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate 05 March 2021
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine 11 February 2021
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 14 December 2020
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 03 November 2020
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 15 July 2020
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges 25 June 2020
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts 22 June 2020
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia 29 April 2020
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program 08 April 2020
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response 24 March 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa 04 March 2020
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters 10 December 2019
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa 20 November 2019
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease 17 October 2019